Terns Pharmaceuticals appoints Heather Turner to board; Ann Taylor resigns

Terns Pharmaceuticals, Inc.

Heather Turner, former CEO of Carmot Therapeutics, appointed to Board of Directors effective Nov 18.
Ann Taylor resigned effective Nov 18; departure not due to any disagreement with company operations.
Turner brings 25 years biotech experience; led Carmot's $3.1B acquisition by Roche.
Turner also appointed to Audit Committee; eligible for standard non-employee director compensation.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Heather Turner

Member of the Board of Directors

TERN · Terns Pharmaceuticals, Inc.

Effective: 2024-11-18
Filed: November 18, 2024, 6:59 PM ET

On November 15, 2024, the Board appointed and elected Heather Turner as a member of the Board, effective as of November 18, 2024.

Departed

Ann Taylor

Member of the Board of Directors

TERN · Terns Pharmaceuticals, Inc.

Effective: 2024-11-18
Filed: November 18, 2024, 6:59 PM ET

On November 14, 2024, Ann Taylor notified Terns Pharmaceuticals, Inc. (the “Company”) of her resignation from the Company’s Board of Directors (the “Board”), effective as of November 18, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Heather Turner was appointed as Member of the Board of Directors at Terns Pharmaceuticals, Inc..

Action: appointed and elected
Role: Member of the Board of Directors

Exact text from the filing

On November 15, 2024, the Board appointed and elected Heather Turner as a member of the Board, effective as of November 18, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ann Taylor resigned as Member of the Board of Directors at Terns Pharmaceuticals, Inc..

Action: resigned
Role: Member of the Board of Directors

Exact text from the filing

On November 14, 2024, Ann Taylor notified Terns Pharmaceuticals, Inc. (the “Company”) of her resignation from the Company’s Board of Directors (the “Board”), effective as of November 18, 2024.

View on SEC.gov

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-127964

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.